Author Correction: Statin treatment after acute coronary syndrome: Adherence and reasons for non-adherence in a randomized controlled intervention trial

Huber, Daniel; Wikén, Christian; Henriksson, Robin; Söderström, Lars; Mooe, Thomas

doi:10.1038/s41598-021-85469-y

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study findings align with previous studies on subjects in Western countries 22,27–31 that highlighted that the patients among the secondary prevention had a higher persistence rate and adherence to statins than those among the primary prevention. The results also align with the finding that females were likely to discontinue the therapy among the secondary prevention population 30,32,33 . However, the results are inconsistent in that almost no sex difference was found in primary prevention 30,32 .…”

Section: Discussionsupporting

confidence: 79%

See 1 more Smart Citation

Statin persistence and adherence among older initiators: A nationwide cohort study using the national health insurance claims database in Japan

Tomida

Yoshida

Senda

et al. 2023

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose This study clarifies the reality of persistence and adherence to statins in older Japanese people who initiated statin use and compares it between primary and secondary prevention cohorts. Methods The nationwide study using the national claims database targeted statin initiators aged ≥55 years from FY2014 to FY2017 in Japan. Persistence and adherence to statins were analyzed overall and according to subgroups based on sex, age stratum, and prevention cohorts. Permissible gap of median days that statins were supplied per prescription to an individual was employed. Persistence rates were estimated as Kaplan–Meier estimates. Poor adherence during persistence was evaluated and defined as <0.8 of the proportion of days covered. Results Of 3 675 949 initiators, approximately 80% initiated statin use with strong variants. The persistence rate at 1 year was 0.61. Poor adherence to statins during persistence was 8.0% in all patients and this value gradually improved with increasing age. Persistence rate and adherence were lower for the primary prevention cohort than for the secondary prevention cohort, and a notable sex difference was observed for the secondary prevention cohort, which was lower in females but was almost never and slightly observed in the primary prevention cohorts without and with high‐risk factors, respectively. Conclusions Many statin initiators discontinued statins shortly following statin initiation but adherence while on statin therapy was good. Attentively watching older patients not to discontinue statins and listening to their reasons for discontinuation are required, especially for initiators in primary prevention and females in secondary prevention.

show abstract

Section: Discussionsupporting

confidence: 79%

“…The results also align with the finding that females were likely to discontinue the therapy among the secondary prevention population. 30,32,33 However, the results are inconsistent in that almost no sex difference was found in primary prevention. 30,32 We found a study including older population in Asia.…”

Section: Discussionmentioning

confidence: 99%

Statin persistence and adherence among older initiators: A nationwide cohort study using the national health insurance claims database in Japan

Tomida

Yoshida

Senda

et al. 2023

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…Сложившееся к началу текущего столетия терминологическое многообразие, описывающее отношение пациента к исполнению медицинских предписаний, впоследствии продолжало расширяться, как за счет введения в оборот синонимов, так и за счет придания определениям смысловых www.jscientia.org нюансов. С другой стороны, во многих источниках термины комплаенс, приверженность и близкие к ним стали использоваться как взаимозаменяемые синонимы [1,[9][10][11].…”

Section: терминологияunclassified

“…У больных ишемической болезнью сердца (ИБС) в качестве такой точки часто служит поступление в стационар по поводу острого коронарного синдрома (ОКС), инфаркта миокарда или нестабильной стенокардии. Дальнейшее изучение траекторий изменения приверженности в целом и по отдельным группам препаратов происходит в течение длительного промежутка времени (в среднем от 6 месяцев до года, но иногда и нескольких лет) с учетом наличия или отсутствия в наблюдаемых группах пациентов потенциальных барьеров и предикторов приверженности [10,38].…”

Section: особенности приверженности лечению больных после острого кор...unclassified

“…C женским полом в одних работах выявляется позитивная связь с приверженностью [27,31]; в других -говорится о более низкой приверженности женщин [10], в третьих -не обнаруживается подобных закономерностей [41,43]. Есть мнение, что женщины после перенесенного ОКС проявляют худшую приверженность к гиполипидемическим препаратам, чем мужчины, тогда как половые отличия в приверженности к другим препаратам отсутствуют [44].…”

Section: особенности приверженности лечению больных после острого кор...unclassified

See 1 more Smart Citation

Adherence to Treatment of Cardiac Patients: Approaches to Assessment, Ways to Increase and Prognostic Value

Kholkina,

Isakov,

Timofeev

2023

Juvenis Scientia

View full text Add to dashboard Cite

Adherence to treatment is understood as a complex model of the patient’s behavior in relation to their health, implemented in the degree of compliance of such behavior with respect to the recommendations received from the doctor regarding medications, self-control algorithms, diet and other lifestyle change measures. Adherence can be assessed by determining drug metabolites in body fluids (blood, urine) and using various questionnaires. At the same time, an important role in increasing adherence to therapy is assigned to the attending physician, without contact with which most patients make an independent decision to stop taking all or some of the prescribed drugs or to make an unreasonable correction of their dosages. Among the factors influencing the decrease in adherence to treatment of cardiac patients are the patient’s misunderstanding of their disease and the expected effects of therapy, fears of undesirable effects of therapy, a low level of motivation, a tendency towards forgetfulness and some others. Comorbidity and related polypharmacy also contribute to non-adherence, especially multiple drugs are prescribed simultaneously by various specialists — therapists, endocrinologists, urologists, neurologists, ophthalmologists. At the same time, there is a clear increase in undesirable consequences (repeated hospitalizations due to myocardial infarction and other cardiovascular events) in non-adherent patients 6 months after the previous coronary event and a significantly higher risk a year later. Increasing adherence to treatment is the task of medical workers, starting from the inpatient stage of treatment (clear recommendations noted in the discharge documents), followed by the support of outpatient doctors, explaining the need to take certain medications, and ending with monitoring the execution of medical prescriptions.

show abstract

Statin Intolerance: An Overview for Clinicians

Surma

Lewek

Penson

et al. 2023

Contemporary Diabetes

View full text Add to dashboard Cite

Author Correction: Statin treatment after acute coronary syndrome: Adherence and reasons for non-adherence in a randomized controlled intervention trial

Abstract: An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cited by 4 publications

References 0 publications

Statin persistence and adherence among older initiators: A nationwide cohort study using the national health insurance claims database in Japan

Statin persistence and adherence among older initiators: A nationwide cohort study using the national health insurance claims database in Japan

Adherence to Treatment of Cardiac Patients: Approaches to Assessment, Ways to Increase and Prognostic Value

Statin Intolerance: An Overview for Clinicians

Contact Info

Product

Resources

About